"Early and very early discharge in patients undergoing TAVI, supported by close follow-up using Tucuvi’s AI, was shown to be safe and efficient."
"Tucuvi's AI demonstrated excellent feasibility with 90% adherence, higher than prior app-based solutions. It effectively monitored MBO symptoms, enabling timely clinical interventions and enhancing patient engagement."












